Microviable Therapeutics will participate in Microbiome Connect USA that will take place from November 14th to 16th in Boston.
Claudio Hidalgo Cantabrana, CEO at Microviable, will join a like-minded community of 300 scientists and entrepreneurs passionate about the microbiome. Claudio will moderate a roundtable discussion on infectious diseases (November 16th, 8:00 am to 8:40 am) with other prominent leaders in the field to discuss how to optimize microbiome therapeutics for the treatment and prevention of communicable diseases.
In addition, Claudio Hidalgo will be giving a presentation (Nov. 16th, 10:30am) to showcase our lead candidate MVT-201, a complete microbiota ecosystem product. MVT-201 is the first biological drug that solely contains the complete microbial fraction of the gut microbiota. It has has shown safety and efficacy in various murine models, with more than 95% efficacy to resolve MDR-pathogenic bacteria. Claudio will give an overview also on the future plans for this product and the enabling technology of our proprietary PharmaBiota® platform.
During the preclinical programme showcase, Claudio will be joined by Egle Katkeviciute, Head of Research at Wyss Zurich Translational Center at UZH, and Peter Nara, CEO at Keystone Bio. The three speakers, will give a presentation of their most recent preclinical data that are about to transform the therapeutic landscape of the microbiome.
Microbiome Connect is the leading partnering conference for microbiome therapeutics & live biotherapeutic products. It’s a chance for senior executives to address shared challenges around innovative therapeutic development, build meaningful partnerships, and sharpen their R&D and commercial strategies.
